Table 1:
Characteristics of the 71 sarcoma patients with isolated lung metastasis at the time when the metastases were detected.
| Variable | Group A (N = 29) | Group B (N = 17) | Group C (N = 25) | P-value (for comparison between Groups A and B) |
|---|---|---|---|---|
| Gender | ||||
| Males | 17 (58.6%) | 9 (52.9%) | 14 (56.0%) | 0.71 |
| Females | 12 (41.4%) | 8 (47.1%) | 11 (44.0%) | |
| Sarcoma type | ||||
| Osteosarcoma | 14 (48.3%) | 8 (47.1%) | 10 (40.0%) | 0.94 |
| Non-osteosarcoma | 15 (51.7%) | 9 (52.9%) | 15 (60.0%) | |
| Mean age at detection of metastases (years) | 31.9 | 27.6 | 38.4 | 0.28 |
| Site | ||||
| Upper extremity | 8 (27.6%) | 4 (23.5%) | 2 (8.0%) | 1.00 |
| Lower extremity | 17 (58.6%) | 11 (64.7%) | 16 (64.0%) | |
| Trunk | 1 (3.4%) | 1 (5.9%) | 1 (4.0%) | |
| Urogenital | 2 (6.9%) | 1 (5.9%) | 3 (12.0%) | |
| Head and neck | 1 (3.4%) | 0 | 0 | |
| Pelvic | 0 | 0 | 2 (8.0%) | |
| Retroperitoneal | 0 | 0 | 1 (4.0%) | |
| Histological grade | ||||
| ND/not applicable | 1 (3.4%) | 2 (11.8%) | 1 (4.0%) | 0.82 |
| 1 | 2 (6.9%) | 1 (5.9%) | 0 | |
| 2 | 2 (6.9%) | 2 (11.8%) | 4 (16.0%) | |
| 3 | 24 (82.8%) | 12 (70.5%) | 20 (80.0%) | |
| No. of metastatic nodules | ||||
| <3 | 13 (44.8%) | 3 (17.6%) | 0 | 0.014 |
| ≥3 | 14 (48.3%) | 14 (82.4%) | 23 (92.0%) | |
| ND | 2 (6.9%) | 0 | 2 (8.0%) | |
| Size of metastatic nodulesa (cm) | ||||
| <2 | 10 (34.5%) | 9 (52.9%) | 7 (28.0%) | 0.29 |
| ≥2 | 14 (48.3%) | 5 (29.4%) | 14 (56.0%) | |
| ND | 5 (17.2%) | 3 (17.7%) | 4 (16%) | |
| Laterality of nodules | ||||
| Unilateral | 17 (57.1%) | 5 (6.7%) | 2 (8.0%) | 0.001 |
| Bilateral | 12 (42.9%) | 14 (93.3%) | 23 (92.0%) | |
| Mean follow-up time from first detection of lung metastases: days (95% CI) | 764 (590–938) | 340 (229–451) | 257 (144–370) | 0.0049 |
| Mean disease-free interval: months (95% CI) | 12.9 (8.3–17.4) | 8.9 (2.4–15.4) | 4.6 (1.9–7.4) | 0.086 |
ND: no data or data were uncertain.
aThe maximum diameter (cm) of the largest metastatic lung nodule.